Navigation Links
Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
Date:10/14/2008

. Based on the current expected level of receipts and expenditures, the company believes that its cash and cash equivalents are sufficient to support its activities into the fourth quarter of fiscal year 2009. The company will be eligible to receive a minimum milestone payment of $20 million from its U.S. partner, Strativa Pharmaceuticals, in the event that the planned NDA submission results in the company receiving marketing approval for ONCONASE.

Clinical/Regulatory Update

Alfacell has completed patient enrollment in a confirmatory Phase IIIb clinical trial for ONCONASE in patients suffering from unresectable malignant mesothelioma (UMM) and reached the required number of evaluable events to conduct the formal statistical analyses required to complete the final sections of the ONCONASE rolling NDA. As the company has previously reported, the results of the preliminary statistical analysis of the data did not meet statistical significance for the primary endpoint of survival in UMM. However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen, a pre-defined primary data set for this sub-group of patients in the trial, which represents a currently unmet medical need. Alfacell has requested a pre-NDA meeting with the Food and Drug Administration (FDA) to discuss the details of the planned NDA submission. The company continues to estimate that the final components of the rolling NDA will be submitted by the end of 2008, and the company plans to present the results of the Phase IIIb trial at an upcoming scientific conference in 2009.

The company has completed enrollment in its Phase I clinical trials for patients suffering from non-small cell lung cancer (NSCLC) and other solid tumors and is planning for a follow-on Phase II clinical trial in NSCLC patients that exhibit resistance to platinum based chemotherapy regimens. Initiation of patient enrollment in this tria
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
2. Alfacell Hires Advisors to Advance Strategic Alternatives
3. Alfacell Receives NASDAQ Delisting Letter
4. Alfacell Receives NASDAQ Non-Compliance Notification
5. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
6. Alfacell Announces Retirement of Chief Executive Officer
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
11. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , ... September 02, 2015 , ... ... of botanical and plant-derived compounds. BCC Research reveals in its new report ... because this market defines the category and generates the most market demand. ...
(Date:9/2/2015)... SAN FRANCISCO, Calif. , Sept. 2, 2015 /PRNewswire/ ... that Bonnie H. Anderson , president and chief ... Healthcare Conference on Wednesday, September 16, 2015 at 10:30 ... . The live audio webcast and ... http://investor.veracyte.com . The webcast will be available shortly after ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... aid high-risk surgeries. From vital sign monitoring in ICU to 3D skull printing ... surgeon to make real-time clinical decisions with simultaneous access to high precision medical ...
(Date:9/2/2015)... ... September 02, 2015 , ... Genedata, a leading provider ... Genedata Screener ® version 13.0 at ELRIG Drug Discovery 2015. This latest ... rich set of new capabilities. Screener now supports High Throughput Flow Cytometry (HT-Flow) ...
Breaking Biology Technology:Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4
... Integrated Knowledge Center Outside the United States. , ... ... Knowledge Center (DKC) today, 17 months after breaking ground last summer. ... the city’s Genome Valley, the center will be a research hub ...
... York, Nov. 21 Eli Lilly and,Company (NYSE: ... ) today,announced the successful completion of the previously announced tender ... of ImClone at a price of $70.00 per share in ... November 20, 2008. , ...
... New hire brings over 20 years of commercial life sciences ... SAN DIEGO, Nov. 21 Cyntellect, a privately-held life ... analysis and manipulation systems, announced today that it has appointed ... America. Andre will be responsible for the sales of Cyntellect,s ...
Cached Biology Technology:DuPont Opens Research & Development Center in India 2DuPont Opens Research & Development Center in India 3Lilly Completes Cash Tender Offer for ImClone Systems 2Lilly Completes Cash Tender Offer for ImClone Systems 3Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America 2
(Date:8/24/2015)... , August 24, 2015 The consulting ... ,s largest biometrics manufacturer DERMALOG and its customized solutions and ... African Biometrics Company of the Year Award". DERMALOG is particularly ... .   -Cross reference: Picture is available ... - On Thursday evening, in South ...
(Date:8/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... Alliance and the EMV Migration Forum.  ... Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. direct ... promoting adoption of smart card technology. To ...
(Date:8/17/2015)... 17, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... for Q4 2015. The new marketing campaign is being ... Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( ... leader in retail driven marketing and brand awareness and ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... March 8, 2010 Spinal Muscular Atrophy (SMA) is ... is available. SMA affects approximately 1 in 10,000 live ... mortality and the second most common autosomal recessive disorder, ... Genetics recommends carrier testing for all couples, the American ...
... During the school day, children eat roughly one-third ... lunch, breakfast and snacks may be served, providing ample ... With economical constraints interfering with schools to provide ... a study in the March/April issue of the ...
... Pediatrics researchers have identified the first major gene ... food allergy called eosinophilic esophagitis (EoE). In this disease, ... difficulties, a patient may be unable to eat a ... association study, the study team found EoE was linked ...
Cached Biology News:Is prenatal screening for rare diseases like spinal muscular atrophy too costly? 2Farm-to-school programs motivate school food service professionals 2Farm-to-school programs motivate school food service professionals 3Gene site found for children's food allergy 2
Mouse Anti-Human Killer Cell Immunoglobulin-like Receptor, Two Domains, Long Cytoplasmic Tail, 2 (KIR2DL2 (KIR2DL3 Monoclonal Antibody Family: Immunoglobulin Sub-Family: not assigned-Immunogl...
Chicken Anti-Human Stomatin-like 2 (STOML2 Polyclonal AntibodyNew Applications: ELISA, Western Blot...
Mouse Anti-Human Kallikrein 2 (Hk2)...
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
Biology Products: